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INTRODUCTION 
 
Diabetes Mellitus comprises a group of common metabolic disorder that shares the 
phenotype of hyperglycemia. Several distinct type of DM exists and is caused by 
complex interaction of genetic, environmental factors and lifestyle choices.  
 
The two broad categories of DM are designated as Type 1 and Type 2 Diabetes. 
 
Type 1 Diabetes occurs due to auto-immune Beta cell destruction. 
 
Type 2 DM is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion and increased glucose 
production. 
 
The chronic complication of DM affects many organ systems and is responsible 
for the majority of morbidity and mortality associated with the disease. The 
vascular complication of DM are further subdivided into Micro-vascular 
(Retinopathy, neuropathy, nephropathy) and Macro-vascular (coronary artery 
disease, peripheral arterial disease and cerebro-vascular disease). 
 
The micro-vascular complications of both Type 1 and Type 2 DM result from 
chronic hyperglycemia. Since type 2 DM often has a long asymptomatic period of 
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hyperglycemia, many individuals with Type 2 DM have complications at the time 
of diagnosis. 
 
The evidence implicating a causative role of chronic hyperglycemia in 
macrovascular complications is less conclusive. Moreover coronary heart disease 
events and mortality are two to four times greater in patients with Type 2 DM. 
Other factors like dyslipidaemia and Hypertension play an important role in macro 
vascular complications. 
 
PRESENT STUDY 
The present study was done on the patients with age more than 35 years with DM 
Type 2 attending the out-patient department of Diabetology at Government 
Stanley Medical College & Hospital, Chennai. These patients primarily belong to 
Lower socio-economic strata of the Society. 
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AIM OF THE STUDY 
 
(1) To evaluate the microvascular and macrovascular complications of Type 2 
Diabetes Mellitus, attending the Diabetology Out-Patient Department at 
Government Stanley Hospital, Chennai. The Patients were categorised 
according to the duration of diabetes for the purpose of study into 
 
(a) Newly diagnosed DM. 
(b) DM of <  5 years. 
(c) DM for 5 – 10 years. 
(d) DM > 10 years. 
 
(2) To evaluate the Risk factors such as hypertension, obesity, 
hypercholesterolemia and smoking. 
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REVIEW OF LITERATURE 
 
DIABETES MELLITUS 
 
INTRODUCTION 
 
Diabetes Mellitus is a group of metabolic diseases characterized by chronic 
hyperglycemia associated with disturbances of carbohydrate, fat and protein 
metabolism due to absolute or relative deficiency in insulin secretion and/or 
action. Diabetes causes long term damage, dysfunction and failure of various 
organs; especially the eyes, kidneys, nerves, heart and blood vessels. In a nutshell 
diabetes is appropriately described as a “Metabolic cum Vascular disorder” 1. 
 
Recently the World Health Organization in consultation with an expert committee 
of the American Diabetes Association has reported a new classification and 
diagnostic criteria2. The term insulin dependent diabetes mellitus and non-insulin 
dependent diabetes mellitus and their acronyms, IDDM and NIDDM are 
eliminated. These terms have been confusing and have frequently resulted in 
classifying the patient based on treatment rather than etiology. 
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ETIOLOGICAL CLASSIFICATION OF DIABETES MELLITUS 
Type 1      
Auto immune 
Idiopathic      
 
Type 2 
Predominantly insulin Resistance 
Predominantly insulin secretory defects 
  
Other Specific Types        
   
Genetic defects of beta cell dysfunction e.g., MODY 1 to 4    
Genetic defects in insulin action e.g., Type A insulin resistence 
 Diseases of Exocrine pancreas, e.g., Fibro calculus pancreatopathy 
Endocrinopathies, e.g., Acromegaly, Cushings, etc., 
Drugs or chemical induced, e.g., glucocorticoids 
Infections, e.g., congenital rubella 
Uncommon forms of immune mediated diabetes, e.g., Stiff Man 
Syndrome 
Other Genetic syndromes. 
 
Gestational Diabetes 
 
STAGES OF DIABETES 
Stages of diabetes range from normal glucose tolerance, through IGT and IFG 
(impaired fasting glucose), into frank diabetes mellitus, which may be non-insulin 
requiring, insulin requiring for control and insulin requiring for survival. Type 1 
DM can be found across the whole spectrum. In the early stages of treatment there 
can be a period of non-insulin requirement, but later followed by insulin 
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requirement for survival. In type 2 DM, insulin may be required during a period of 
ketoacidosis precipitated by severe stress or infection. 
 
DIAGNOSIS of DM 
a. Diabetes is diagnosed if the fasting value ≥126mg or a 2-hour plasma 
glucose ≥ 200mg. 
b. Impaired Glucose Tolerance is present when the fasting level is ≤126 
mg and two-hour value is in the range of 140-200mg/dl 
c. Impaired fasting glucose is present when the fasting level is ≥100 and ≤ 
and two hour value is ≤ 140mg/dl. 
d. Glucose Tolerance is normal when the fasting and the 2-hour values are 
less than 100mg and 140 mg respectively. 
e. Diagnostic criteria for gestational diabetes is different. 
 
AETIOPATHOGENESIS OF TYPE 2 DM 
The role of genetic factors in the etiology of type 2 DM has been appreciated ever 
since the recognition of the disease. Studies of identical twins revealing 10% 
concordance for type 2 DM have highlighted the single dominant influence of 
genetic factors in the etiology of type 2 DM. This concordance was recorded 
independent of obesity and even when the index twin and co twin lived in different 
environment. Earlier attempts to invoke a simple Mendalian type of inheritance, 
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viz., autosomal dominant, autosomal recessive and sex-linked inheritance met 
variable results. It was only subsequently recognized that the diabetic genotype 
might be modified by other factors, which ultimately influence the phenotypic 
expression. Similarly, attempts to quantify the risk in the inheritance of diabetes 
mellitus met with variable results. Diabetic genotype is influenced by various 
other factors the predominant one being central obesity. Even though obesity per 
se does not produce diabetes mellitus, it nevertheless precipitates the disease in 
susceptible individual. Epidemiological studies have established the significant 
contribution by other factors such as physical indolence, dietary habits 
(independent of obesity), viz., consumption of refined carbohydrates and reduced 
intake of fiber, urbanization with associated affluence and the stress of life, in the 
etiology of type 2 DM. 
 
The current understanding type2 DM is that it involves triple abnormalities in the 
genesis of hyperglycemia, 1) impaired pancreatic insulin secretion, 2) peripheral 
resistance to insulin action occurring primarily in liver muscle, and 3) excessive 
hepatic glucose output. The classical glycemic profile of type 2 DM consists of 
elevated basal or fasting levels upon which postprandial glycemic excursions are 
superimposed. The hepatic glucose output is the principal factor for fasting 
hyperglycemia and the post prandial hyperglycemia in large part is determined by 
the peripheral glucose utilization (Insulin resistance)3. 
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1.Impaired Panreatic Insulin Secretion: The beta cell dysfunction in diabetics 
fall into two distinct types. a) the pulsatile insulin delivery is lost even when the 
glucose tolerance is normal and b) the loss of compensatory mechanism, which 
include increase beta cell mass, quantitative insulin output and maximum secretary 
capacity. 
a) Insulin Secretion in type 2 DM: The normal fasting insulin level is 
between 5 and 15µU/ml. It may be low (<5µU/ml) in subjects with high 
insulin sensitivity and elevated (>15µU/ml) in insulin resistant subjects. 
Normally insulin is secreted in a pulsatile fashion and also secreted in 
response to meals and or secretagogues. The pulsatile secretion is called 
ultradian oscillations. The ultradian pulse  of insulin secretion occur 90 
to 120 minutes and are exaggerated after the ingestion of food. Besides 
the ultradian pulsations, rapid oscillations of insulin level occur every 8 
to 16 minutes in the beta cell. These rapid oscillatory insulin pulses are 
effective in inhibiting hepatic glucose output. 
 
The insulin secretion following a glucose load shows a biphasic 
response. The first phase acute insulin response (AIR) is due to release 
of insulin stored in the granules, which suppresses the hepatic glucose 
output. This occurs within 4 to 5 minutes and returns to normal within 
10 minutes. The second phase is in response to the ambient raise in the 
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glucose level, which promotes disposal of glucose in peripheral tissue 
(Muscle and adipose tissue). 
 
b) Beta cell dysfunction: The beta cell mass is mildly reduced especially 
when obesity is taken into account. Amyloid deposits are frequently 
observed in the islets. Morphologically islets appear normal and insulitis 
is never present. Amylin or the islet Amyloid polypeptide is a 37 amino 
acid protein normally produced by the beta cells and co-packaged with 
insulin in the secretary granules and co-secreted in the sinusoidal space. 
For reasons unknown this material tends to get accumulated 
extracellularly in close contact with beta cells and forms fibrils. Amylin 
has been reported to lower basal and insulin stimulated glycogen 
synthatase in the muscles and to inhibit glucose stimulated insulin 
secretion. These abnormalities of deficient insulin secretion and insulin 
action are similar to the pathogenic factors of type 2 DM. 
 
There are evidences of impaired beta cell response to glucose (blindness 
of beta cells to glucose) but acute insulin response to non-glucose 
stimulus like arginine, neurotransmitters and hormones persist. 
 
 
 
 10
 
Insulin Secretory Abnormalities in Type 2 Diabetes Mellitus 
 Decreased glucose sensing 
- Impaired ability to respond to elevations and reductions in glucose 
during glucose infusion. 
- Reduced or absent first-phase insulin secretion in response to 
intravenous glucose administration. 
 Reduced or absent early insulin secretory response to oral glucose 
 Alterations in the rapid oscillations of insulin secretion 
 Reduced effect of gastrointestinal hormones in potentiating glucose 
mediated insulin secretion. 
 Inadequate insulin secretion for the magnitude of hyperglycemia. 
 
2. Peripheral Resistance to Insulin: Numerous longitudinal and cross sectional 
studies have provided evidences that hyperinsulinemia antedates the development 
of type 2 DM. This insulin resistance can occur in various tissues, liver, muscle, 
splanchnic, etc. After glucose ingestion insulin is released into the portal vein and 
is carried to the liver where it binds to its specific receptors on the hepatocytes 
and suppresses the hepatic glucose output. Failure of the liver to perceive this 
signal results in the increased hepatic glucose output and is manifested as raised 
blood glucose levels in type 2 DM. 
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In muscles the defects in action are  
1) impaired insulin receptor tyrosinekinase activity, 
2) diminished glucose transporters and  
3) Diminished glycogen synthatase and pyruvate dehydrogenase. 
These defect results in disturbances in major intracellular pathways of glucose 
disposal namely glycogen synthesis and glucose oxidation. 
 
In type 2 DM subjects both receptor and post receptor defects have been shown to 
contribute to insulin resistance. Post binding defects are of three types a) impaired 
generation of insulin’s second messenger b) diminished glucose transport into the 
cell and c) a post glucose transport abnormality in some critical step involved in 
glucose utilization. In diabetic subjects with moderate to severe hyperglycemia 
post binding defects in insulin action are responsible for the insulin resistance. In 
subjects with impaired glucose tolerance the defect may be at insulin binding to 
its receptor. 
 
NATURAL HISTORY OF TYPE 2 DM 
 
Normal glucose homeostasis is dependent on a finely balanced dynamic 
interaction between tissue sensitivity to insulin and insulin secretion. This 
evolution of the disease process in type 2 DM requires the defects in both insulin 
secretion and insulin action. 
 12
 
With the decline in insulin sensitivity, the endogenous insulin secretion increases 
to maintain normal fasting plasma glucose. As the disease progresses, the 
compensatory insulin secretion diminishes and the fasting plasma glucose rises. 
 
PATHOGENESIS OF HYPERGLYCEMIA IN TYPE 2 DM 
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CHRONIC COMPLICATIONS 
INTRODUCTION 
The quality and expectancy of life of people with Diabetes, whether Type 1 or 
Type 2 is profoundly influenced by the development of complications and by how 
far and how fast they progress. 
 
Complications may be diabetes specific mainly affecting the microvasculature (the 
triad of retinopathy, nephropathy and neuropathy) or they may be macrovascular 
in nature and present as coronary artery disease, cerebro vascular disease or 
peripheral vascular disease for which the incidence is 3 to 6 fold greater than 
normal with diabetes. 
 
The Diabetic control and complication trial4 provided definite proof that reduction 
in chronic hyperglycemia can prevent many of the early complication of Type 1 
DM. 
 
The United Kingdom Prospective Diabetes Study (UKPDS)5 studied the course of 
about 5000 individuals with Type 2 DM for more than 10 years. The UKPDS 
demonstrated that there was a continuous relationship between glycemia control 
and development of complication. One major finding in UKPDS was that strict 
blood pressure control significantly reduced both macro and micro vascular 
complications. 
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Similar reduction in the risk of retinopathy and nephropathy ware demonstrated 
with intensive glycemia control in Kumamoto study3. 
 
The findings of DCCT, UKPDS and Kumamoto studies supports the idea that 
chronic hyperglycemia plays a causative role in the pathogenesis of diabetes 
microvascular complications. 
 
These landmark studies prove the value of metabolic control and emphases the 
importance of  
(1) intensive glycemic control in all forms of DM. 
(2) Early diagnosis and strict blood pressure control in Type 2 DM. 
 
MICROVASCULAR COMPLICATIONS 
DIABETIC RETINOPATHY 
DM is a leading cause of blindness between the age of 20 and 74. The risk of 
blindness is 25 times greater in diabetes than in non-diabetics3. The incidence of 
Diabetic Retinopathy is related more to the duration of Diabetes than any other 
factor. Blindness is primarily the result of progressive diabetic retinopathy and 
clinically significant macular oedema. 
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PATHOPHYSIOLOGY: Diabetic Retinopathy is a micro-angiopathy affecting 
retinal precapillary arterioles, the capillary and venules. There are basically two 
factors responsible for Diabetic Retinopathy. They are 
 
(1) Microvascular occlusion due to changes in capillary endothelium. 
(2) Microvascular leakages due to pericyte drop out. 
 
Classification of Diabetic Retinopathy 
 ETDRS Classification – (Early Treatment of Diabetic Retinopathy Study)6 
I. Non Proliferative Diabetic Retinopathy. 
(a) Mild 
Atleast 1 Micro aneurysm. 
(b) Moderate 
Soft exudate, venous beading and intra retinal 
microvascular abnormalities (IRMA). 
(c)      Severe 
Haemorrhages/ microaneurysm in all 4 quadrants of 
Retina. 
(d)      Very Severe 
    Any 2 or more of (c). 
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II. Proliferative Diabetic Retinopathy 
Composed of new vessels on Disc (NVD) or New Vessels 
Elsewhere (NVE), preretinal or vitreous haemorrhages, Fibrous 
tissue proliferation. 
 
III. Clinically Significant Macular Edema (CSME) 
 
Other complications of Diabetes in the eye are 
 Cataract – Diabetic cataracts are seen at an earlier age and they also 
 mature faster. 
 
 Glaucoma - Open angle Glaucoma is more common in the 
 diabetic population. 
 Optic neuritis/Anterior Ischemic Optic Neuropathy 
 Extraocular Muscle Palsies   – causing sudden onset of Diplopia. 
 
DIABETIC NEPHROPATHY 
 
Diabetic Nephropathy is clinically defined by the presence of persistent 
proteinuria of more than 500 mg/day in a diabetic patient who has concomitant 
diabetic retinopathy and hypertension and in the absence of clinical or laboratory 
evidence of other kidney or renal tract disease. The presence of diabetic 
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retinopathy is an important pre-requisite because in its absence albuminuria in a 
Type 2 Diabetic patient may be due to diabetic or non diabetic glomerulosclerosis 
and the chances for both are equal7. 
 
Diabetic Nephropathy is the leading cause of chronic renal failure worldwide. It is 
also one of the most significant long-term complication in terms of morbidity and 
mortality for individual patients with diabetes. The mortality rate from all causes 
in diabetic patients with nephropathy is 20 to 40 times higher than that of patients 
without nephropathy. 
 
Increased Prevalence of Diabetic Nephropathy in South Asians: Racial 
differences in the prevalence of diabetic renal disease between the people of Asian 
ethnic origin and white Caucasians have been reported in the UK. Samanta et al8 
had studied the prevalence of diabetic complications among Indo-Asians and 
white Caucasians. It was found in this study that renal diseases are more common 
among the Indo Asian people with diabetes when compared to white Caucasians 
and this difference remained significant after adjusting for age, sex, duration of 
diabetes, age at diagnosis, hypertension, smoking and treatment with or without 
insulin. 
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Natural Course of Diabetes Nephropathy 
According to Mogensen9, the course of diabetic nephropathy is mainly 
characterized by changes in urinary albumin excretion and GFR while in Type 1 
Diabetic patients the course is well defined and progresses through fine stages. 
 
In Type 2 Diabetes, the course of diabetes nephropathy is less well characterized 
due to the often unknown date of onset of disease or other factors influencing 
progression of nephropathy, such as hypertension, age and other components of 
the metabolic syndrome. Patients with diabetic nephropathy especially with Type 
2 diabetes have a high cardiovascular risk. Vijay et al10 showed that the risk of 
cardiovascular disease was three fold higher in South Indian Nephropathic 
subjects when compared with their non-nephropathic counterparts. Thus in Type 2 
diabetes, many patients may not reach end stage renal disease due to premature 
death from CVD. 
 
Pathophysiology: The pathogenesis of diabetic nephropathy is multifunctional 
genetic susceptibility has been proposed to be an important factor in the 
development and progression of diabetic nephropathy. 
 
The key change in diabetic glomerulopathy is augmentation of extracellular 
material. The earliest morphologic abnormality in diabetic nephropathy is the 
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thickening of the GBM and expansion of the mesangium due to accumulation of 
extracellular matrix. Three major histologic changes occur in the glomeruli in 
diabetic nephropathy. They are: 
(1) Mesangial expansion is directly induced by hyperglycemia via 
increased matrix production. 
(2) Glomerular basement membrane thickening and 
(3) Glomerular sclerosis is caused by intraglomerular hypertension. 
 
Causes of Diabetic Nephropathy:  The exact cause of Diabetic Nephropathy is 
still unknown but the mechanism postulated are 
¾ Hyperglycemia causing hyperfiltration and renal injury. 
¾ Advanced glycation products (AGE) 
¾ Activation of cytokines 
In addition to renal haemodynamic alteration, patients with overt diabetic 
nephropathy (dipstick positive proteinuria and decreasing GFR) generally develop 
systemic hypertension. Hypertension in an adverse factor in all progressive renal 
diseases and seems especially so in diabetic nephropathy. 
 
DIABETIC NEUROPATHY 
Diabetic Neuropathy occurs in approximately 50% of individuals with long 
standing Type 1 and Type 2 Diabetes11. It may manifest as polyneuropathy, 
mononeuropathy and autonomic neuropathy. As with the complications of DM, 
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the development of neuropathy correlates with the duration of diabetic and 
glycemic control; both newer myelinated and unmyelinated nerve fibers are lost.  
 
CLASSIFICATION OF DIABETIC NEUROPATHIES 12 
CLINICAL 
POLYNEUROPATHY 
 
Sensory 
 
Chronic sensorimotor 
 
Acute sensory 
 
Autonomic 
 
Cardiovascular 
 
Gastrointestinal 
 
Genitourinary 
 
Miscellaneous 
 
Proximal motor(amyotrophy) 
 
Truncal 
MONONEUROPATHY 
 
Cranial  
Isolated peripheral 
 
 
Mononeuritis multiplex  
 
Truncal 
 
Pathology & Pathogenesis:  Two major features contributing to the pathology of 
human diabetic neuropathy are nerve fiber degeneration and gross diseases of the 
blood vessels supplying them. Microangiopathy is probably one of the main 
causes underlying the pathogenesis of diabetic neuropathy13.  
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PATHOGENESIS OF DIABETIC NEUROPATHY14 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES & DIAGNOSIS 
1. Somatic Neuropathy: The most common presentation is chronic 
symmetrical neuropathy often referred in clinical practice by the phrase 
diabetic neuropathy and it predisposes to significant morbidity through foot 
ulceration. Sensory loss predominates although the motor and autonomic 
system is usually sub clinically affected. Dyck and his team from the Mayo 
Clinic 15 have staged Somatic Neuropathy. 
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↑Na+/K+ATPase 
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Hypoxia 
Segmental 
Demyelination 
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          STAGING OF DIABETIC NEUROPATHY 
Stage 0 
No neuropathy ( no symptoms and fewer than two 
abnormalities on formal testing) 
Stage 1   
Asymptomatic neuropathy (two or more abnormalities 
on formal testing with no symptoms) 
Stage 2   
Symptomatic neuropathy (two or more abnormalities on 
formal testing with minor symptoms) 
Stage 3   
Disabling neuropathy (two or more abnormalities on 
formal testing with severe symptoms) 
 
Other important manifestation of Diabetic Neuropathy includes chronic 
distal symmetric neuropathy. There is length dependent pattern of nerve 
damage with sensory loss starting in the toes and spreading in the feet and 
legs in a stocking distribution. The hands tend to get involved after the 
neuropathy has extended above mid-calf. Sensory ataxia due to impairment 
of proprioception can occur in later stages of the disease and can be 
particularly disabling factor that increase risk of ulceration along with 
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severity of neuropathy include callus, deformity vascular disease and/or 
poor skin blood flow. 
 
2. Cranial Nerve Palsies: third and sixth cranial nerves are most commonly 
affected by diabetes. The onset of cranial nerve palsies is acute and they 
tend to occur in older patient16. Recovery is usual and complete within 3 
months. The typical opthalmoplegia of third nerve palsy is often preceded 
by pain and associated with pupillary sparing due to peripheral nature of 
pupillomotor fibers with the third nerve. 
 
Peripheral nerves in diabetes are prone to entrapment palsies examples, 
carpal tunnel syndrome, foot drop, meralgia parasthetica. 
 
AUTONOMIC NEUROPATHY: Diabetic autonomic neuropathy may 
involve any system of the body 
0000 
 
ORGANISATION OF DIABETIC AUTONOMIC NEUROPATHY 
A. Cardiovascular 
¾ Heart rate abnormalities 
¾ Blood Pressure 
¾ Abnormalities –Postural hypotension 
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¾ Diabetic cardiomyopathy 
¾ Silent myocardial ischaemia 
¾ Sudden cardiac death 
B. Gastrointestinal 
¾ Constipation – Colonic atony 
¾ Diabetic diarrhoea – small intestinal dysfunction 
¾ Gastroparesis diabeticorum chronic or acute (Gastric and Duodenal 
atony) 
¾ Dyspepsia, Dysphagia and oesophageal ulcerations (Oesophageal 
atony) 
¾ Faecal incontinence (Anal sphincter weakness) 
¾ High incidence of cholesterol stones (Gall bladder atony) 
C. Urinary 
¾ Impaired Bladder sensation 
¾ Hesitancy, weak stream 
¾ Dribbling, incomplete bladder emptying  
¾ Increased past void residual urine 
¾ Bladder over distension 
¾ Urinary retention 
D. Genital 
¾ Erectile dysfunction 
¾ Ejaculation failure/ retrograde ejaculation 
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¾ Female sexual dysfunction 
E. Sudomotor and thermo regulatory disorders 
¾ Distal anhidrosis 
¾ Gustatory sweating 
¾ Abnormal vasomotor responses 
F. Pupillary and Lacrimal gland dysfunction 
¾ Miosis   
¾ Impaired light reflexes 
G. Other consequences of Diabetic Autonomic Neuropathy 
¾ Disturbances of respiratory control 
¾ Contribution to pathogenesis of diabetic foot 
¾ Aggravation of diabetic state and other neuro endocrine 
abnormalities 
¾ Unawareness of hypoglycemia 
¾ Worsening of diabetic retinopathy 
Autonomic neuropathy in diabetes is a principal cause of foot ulceration. 
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MACROVASCULAR COMPLICATIONS 
Cardiovascular disease is increased in individuals with Type 1 or Type 2 
DM. The Framingham Heart Study17 revealed a marked increase in 
peripheral arterial disease, congestive heart failure, CAD, MI and sudden 
death in DM. 
 
The American Heart Association recently designed DM as a major risk 
factor for cardiovascular disease (same category as smoking hypertension 
and hyperlipidaemia). Type 2 diabetic patient without a prior M1 have a 
similar risk for coronary artery related events as non-diabetic individuals 
who have had a prior myocardial infraction. 
 
The main factor that contribute to the increased incidence of cardiovascular 
disease in diabetic patients are 
 
1. The acceleration of atherosclerotic process leading to macrovascular 
disease. 
2. Development of specific cardiomyopathy. 
3. Progressive microvascular disease. 
4. Development of autonomic neuropathy. 
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Heart disease in diabetic patients include 
(a) coronary artery disease 
(b) small vessel disease 
(c) Diabetic Cardiomyopathy 
(d) Heart failure 
(e) Cardiac autonomic neuropathy 
 
Coronary Artery Disease: Coronary Artery Disease is  twice as frequent in 
diabetic men and four times as frequent in diabetic women after menopause 
compared to the respective non diabetics1. Besides the increased 
prevalence, CAD in diabetic subjects is also characterized by premature 
onset and disproportionately enhanced susceptibility of female diabetics. 
Coronary Artery Disease in diabetics is characterized by greater prevalence 
of triple vessel disease. The distribution of fatty streaks, fibrous plaques 
and coronary stenosis are relatively more.  
 
An abnormal resting ECG (ST-T wave changes, conduction abnormalities, 
chamber hypertrophy and rhythm disturbance and pattern of old myocardial 
infraction has been documented in 40% normotensive ambulant diabetic 
subjects. 
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Pathogenesis: There are many potential risk factors and increased 
likelihood of coronary heart disease. 
1. Hyperglycemia is an independent risk factor for CAD and is 
associated with increased mortality. 
2. Lipid Abnormalities: The most common pattern of dyslipidaemia 
in Type 2 DM patient is elevated triglyceride level and decreased 
HDL levels. 
3. Insulin Resistance (hyper insulinaemia) 
Insulin resistance cluster with elevated Blood Pressure, Obesity, and 
elevated levels of total triglycerides and low levels of HDL. 
Cholestrol and haemostatic abnormalities. 
This clustering of cardiovascular risk factors - the insulin resistance 
syndrome – predicts coronary artery disease in non-diabetic 
individuals and in patients with Type 2 DM. 
4. Obesity: The measurement of BMI reflects the risk of mortality with 
variation in weight. The explanation is that the intra-peritoneal 
adipose tissue is predominantly responsible for the development of 
insulin resistance, because of the higher lipolytic activity and direct 
drainage to the liver through the portal circulation. 
In addition to coronary artery disease, cerebrovascular disease is 
increased in individuals with DM (threefold increase in stroke). 
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Individuals with DM have an increased incidence of congestive heart 
failure (diabetic cardiomyopathy). The etiology of this abnormality 
is probably multi factorial and includes factors such as myocardial 
ischaemia from atherosclerosis, hypertension and myocardial 
dysfunction secondary to chronic hyperglycemia. 
 
DIABETES AND HYPERTENSION: Hypertension is a common, 
important and modifiable risk factor for both the micro and macro vascular 
complications of diabetes. Hypertension is present in 50 – 80% of patients 
with Type 2 diabetes according to modern definition (i.e., above 140/90 
mm/Hg). Hypertension is clearly associated with insulin resistance in Type 
2 DM patient, but the strength and nature of the association is still unclear. 
Microalbuminuria is the best prediction of progression of diabetic 
nephropathy towards the end stage renal failure. The blood glucose level 
correlates with Blood Pressure and may independently relate to 
albuminuria. Obesity magnifies the prevalence and incidence of both DM 
and hypertension 18. 
Types of Hypertension in Diabetes19. 
1. Essential Hypertension 
2. Hypertension subsequent to nephropathy 
3. Isolated systolic Hypertension 
4. Supine Hypertension with orthostatic fall. 
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PATHOGENESIS OF COMPLICATIONS 20 
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METHODOLOGY 
Selection of Cases: 
Patients with type 2 DM aged more than 35 years attending the Diabetology Out-
Patient Department, Government Stanley Hospital were evaluated for  
(A) Risk factors  - Hypertension, Obesity, Smoking & 
Hypercholesterolemia. 
(B) Microvascular Complications – Retinopathy, Nephropathy & 
Neuropathy. 
(C) Macrovascular Complications – CAD, Cerebrovascular Disease, 
Peripheral Vascular Disease. 
(D) For evaluation of complications they were categorised according to 
the duration of diabetes  
1. Newly Diagnosed 
2. DM < 5 Years 
3. DM 5 – 10 Years. 
4. DM > 10 Years. 
A detailed history was recorded in respect of all the subject patients, particularly 
the duration of DM, Smoking, Complications, Family History of DM, etc. 
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The following criteria was taken 
(1) Diagnosis of Diabetes 
Fasting Plasma Glucose > 126mg% 
2 Hrs Plasma glucose > 200mg% 
Criteria for Risk factors: 
(1) Diagnosis of Hypertension21 
Stages  Systolic Diastolic 
Pre Hypertension  120 – 139 80 - 89 
Hypertension Stage 1 140 - 159 90 – 99 
Hypertension Stage 2 > 160 > 100 
 
(2) Obesity 
(a) Body Mass Index = Weight in Kgs / Height in (Meter)² 
Over weight 25 – 30 
Obese  > 30 
(b) Waist circumference22 
Male  > 90 cms 
Female > 80 cms. 
(3) Total Cholesterol23 
  < 200            Normal 
  200 – 239     Borderline High 
   > 240            High 
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Criteria For Microvascular Complications 
1. Diabetic Retinopathy: Ocular Fundus examination by opthalmoscope 
after dilatation of pupils. 
(a) Non proliferating Diabetic Retinopathy: 
Microaneurysm, Haemorrhage, hard exudates 
(b) Proliferative Retinopathy 
New vessels on disc (NVD) 
New vessels elsewhere (NVE) 
(c) Clinically significant macular oedema (CSME) 
¾ Thickening of retina located 500µU/m from the center of macula. 
¾ Hard exudates with thickening of adjacent retina located 
500µU/m from the center of macula. 
¾ Zone of retinal thickening of one disk area or larger in size, 
located one disc diameter from the center of macula. 
2. Diabetic Nephropathy 
(a) Macroproteinuria - Protein excretion of >500 mg/day out of which 
50% is albumin. Macroalbuminuria was tested. Microlbuminuria 
was not tested. 
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(b) Serum Creatinine 
Calculation of GFR done based on Cockcroft Gault Formula 24. 
Estimated creatinine clearance (ml/min) =  
(140 – Age)  X  body weight (kg) 
----------------------------------------------------------------- 
72 X P Creatinine (mg/dL) 
Multiply by 0.85 for Women. 
3. Diabetic Neuropathy 
Symptoms of sensory and motor signs on physical examination were 
done. 
Criteria for Macrovascular Complications 
1. Cardiovascular Disease 
History : Symptoms of Angina – Chest pain 
ECG: 
- LVH 
- Ischaemic Heart Disease – ST – T were checked for changes 
- Features of Old M1 
      Echo: (Taken where necessary as follows) 
- Diastolic dysfunction in HT 
- Regional wall motion abnormalities 
- Ejection Fraction 
2. Peripheral Vascular Disease 
Clinical examination of Peripheral palpable Arteries done. Doppler 
study was done in relevant cases. 
3. Stroke 
History and Clinical examination for stroke was done. 
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OBSERVATIONS & DATA ANALYSIS 
 
Total Number of Patients – 122 
 
Male - 65  (53%) 
Female - 57  (47%) 
 
 
 
TABLE 1 
 
AGE AND SEX DISTRIBUTION 
 
                         Mean Age of Patients  = 54 Years 
 
 Mean Age of Newly Diagnosed Diabetes  =  50 Years. 
 
      MAXIMUM PATIENTS WITH DIABETES ARE BETWEEN  41  -  60  
YEARS. 
 
  
AGE 
(Years) 
MALE FEMALE TOTAL 
N = 122 
 
34 - 40 
 3 2 5  (4%) 
41 - 50 
 19 19 38 (31%) 
51 - 60 
 27 22 49 (40%) 
61 - 70 
 14 11 25 (20%) 
> 70 
 2 3 5 (4%) 
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TABLE - 2 
 
DURATION OF DM 
 
85% of Patients have duration of Diabetes of < 5 Years . 
 
 
DURATION 
OF DM 
MALE FEMALE TOTAL 
 
(n = 122) 
NEW CASE 
 22 19 41 (34%) 
< 5 
 24 20 44 (36%) 
5-10 
 12 12 24 (20%) 
> 10 
 7 6 13 (11%) 
 
 
 
TABLE  -  3 
 
POSITIVE FAMILY HISTORY WITH DM 
 
Positive Family History of DM in 31% of Patients. 
 
 
 
FAMILY HISTORY OF 
DM 
TOTAL  
(n = 122) 
POSITIVE 38  (31%) 
NEGATIVE 84  (69%) 
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DATA ON RISK FACTORS 
 
TABLE - 4 
 
CATEGORY OF HYPERTENSION AND DM 
 
 
Total Number of Patients with Hypertension in Diabetes is 88 (72%) 
 
52% of Patients are in Stage –1 of Hypertension. 
 
Newly Diagnosed Patients with Hypertension are 60%. 
 
 
 
 
CATEGORY NEWLY 
DIAGNOSED
 
(n = 41) 
< 5 YEARS 
 
(n = 44) 
5 – 10 
YEARS 
 
(n = 24) 
10 
YEARS 
 
(n = 13) 
TOTAL 
 
 
(n = 88) 
PRE HT 
120 – 139 
80 – 89 
6 15 4 2  27 (30%) 
STAGE 1 
140 – 159 
90 – 99 
 
12 19 10 6 
 
 
47 (53%) 
STAGE 2 
160/100 AND 
ABOVE 
7 2 1 4 14 (15%) 
 
TOTAL 
 
25 (61%) 36 (89%) 15 (62%) 12 (92%) 88 (72%) 
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TABLE - 5 
 
OBESITY AND DURATION OF DM 
 
                            51% of Newly Diagnosed Patients are Obese/Overweight. 
 
OBESITY 
 
BMI 
NEWLY 
DIAGNOSED 
 
(n = 41) 
 
< 5 YEARS 
 
 
(n = 44) 
5 – 10 
YEARS 
 
 (n = 24) 
10 
YEARS 
 
(n = 13) 
TOTAL 
 
 
(n = 70) 
OVERWEIG
HT 
25 – 30 
17 22 13 6 58 (83%) 
OBESE 
 
> 30 
4 4 2 2 12 (17%) 
 
TOTAL 
 
21 (51%) 26 (59%) 15 (62%) 9 (69%) 70 (57%) 
 
 
   
  
TABLE  -  6 
 
DM AND ABDOMINAL OBESITY 
 
 69% of Patients have Abdominal Obesity based on Waist Circumference. 
 
 
SEX TOTAL (n = 122) 
MALE 43  (66%) 
FEMALE 41  (72%) 
TOTAL 84 (69%) 
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TABLE - 7 
 
DM AND HYPER CHOLESTEROLEMIA 
 
  25 (61% ) of Newly Diagnosed Patients have Hyper Cholesterolemia. 
 
 
TOTAL 
CHOLESTROL 
Mg/dL 
NEWLY 
DIAGNOSED 
 
(n = 41) 
< 5 YEARS 
 
 
(n = 44) 
5 – 10 
YEARS 
 
(n = 24) 
10 YEARS 
 
 
(n = 13) 
200 – 239 
 10 18 9 7 
240 & ABOVE 
 15 17 11 4 
TOTAL 
(n = 99) 
 
25 (61%) 35 (79%) 20 (83%) 11 (85%) 
 
 
 
TABLE – 8 
 
RISK FACTOR AND DM 
 
Most common Risk Factor with DM is Hypercholesterolemia - 91(74%). 
 
Next Common  Risk factor is Hypertension -                              88(72%). 
 
 
RISK 
FACTOR 
MALE FEMALE TOTAL 
n =  122 
HYPERTENSION 
 46 30 76 (62%) 
OBESITY 
 31 39 70(57%) 
SMOKING 
 24 NIL 24(20%) 
HYPERCHOLESTR
OLEMIA 
 
48 43 91(74%) 
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DATA ON MICROVASCULAR COMPLICATION 
 
 
TABLE - 9 
 
MICROVASCULAR COMPLICATION AND DURATION OF DM 
 
 Retinopathy is the most common Microvascular Complication. 
  
Retinopathy (34%), Neuropathy (24%) and Nephropathy (24%) present at the 
time of Diagnosis of DM. 
 
 
MICROVASCULAR 
COMPLICATION 
NEWLY 
DIAGNOS
ED  
(n = 41) 
< 5 YEARS 
 
 
(n = 44) 
5 – 10 
YEARS 
 
(n = 24) 
10 
YEARS 
 
(n = 13) 
TOTAL 
 
 
(n =  122) 
 
RETINOPATHY 
 
14 (34%) 12 (27%) 9(37%) 
 
6(46%) 41(34%) 
 
NEUROPATHY 
 
10(24%) 8(18%) 5(20%) 
 
2(15%) 25(20%) 
 
NEPHROPATHY 
 
 
10(24%) 
 
12(27%) 
 
11(46%) 
 
6(46%) 
 
39(32%) 
 
 
TABLE  -  10 
 
TYPES OF DIABETIC RETINOPATHY   
 
Non-Proliferative Retinopathy is the most common complication in 
Retinopathy. 
 
TYPES 
 
TOTAL 
(n = 41) 
NON PROLIFERATIVE 
RETINOPATHY 36 (88%) 
PROLIFERATIVE 
RETINOPATHY 3 (9%) 
MACULOPATHY 
 2 (5%) 
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TABLE -  11 
 
STAGES OF CKD IN DIABETES  
 
43% of DM Patients with CKD are in Stage 2. No Patients with DM were found 
in Stages 4 & 5 in this study. 
 
 
 
GFR           STAGES OF    
                        CKD  
TOTAL 
 
n = 39 
 
90 – 120 STAGE 1 
 
9 (23%) 
 
60 – 89   STAGE 2 
 
17 (43%) 
 
30 – 59   STAGE 3 
 
13 (33%) 
 
< 30       STAGES 4 & 5 
 
NIL 
 
 
 
 
TABLE - 12 
 
RENAL FAILURE AND DM 
 
11% of DM Patients had Renal Failure. 
 
 
SERUM CREATININE 
 
TOTAL 
n  =  122 
 
< 1.5  mg/dL 
 
109 (89%) 
 
1.5 -  3  mg/dL 
 
13 (11%) 
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DATA ON MACROVASCULAR COMPLICATION 
 
 
TABLE  -  13 
 
CAD AND DM 
 
 32 (72%) of CAD presented in Patients with DM with Duration of < 5 Yrs 
 
 
DURATION 
 
TOTAL 
n = 44 
 
NEWLY DIAGNOSED 
 
13 (29%) 
 
< 5 YEARS 
 
19 (43%) 
 
5-10 YEARS 
 
6 (14%) 
 
>10 YEARS 
 
6 (14%) 
 
 
 
TABLE   -  14 
 
MANIFESTATION OF CAD 
 
45% of Patients with CAD are Asymptomatic. 
 
 
MANIFESTATION 
 
TOTAL 
 
SYMPTOMATIC 
 
 
24 (54%) 
 
ASYMPTOMATIC 
 
 
20 (45%) 
 43
 
 
TABLE  -  15 
 
MACROVASCULAR COMPLICATIONS AND DM  
 
The most common Macrovascular complication is CAD (36%) 
 
 
COMPLICATION 
 
TOTAL 
n = 122 
 
CAD 
 
44(36%) 
 
PERIPHERAL  VASC. 
DISEASE 
 
7(6%) 
 
CVA 
 
12(10%) 
 
 
 
TABLE   -- 16 
 
FASTING BLOOD SUGAR LEVEL AND DM 
 
Mean fasting Blood sugar = 195mg/dL. 
 
75% Patients had poor sugar control. 
 
  
FASTING BLOOD 
SUGAR 
Mg/dL 
NEWLY 
DIAGNOS
ED  
< 5 YEARS 
 
 
5 – 10 
YEARS 
10 
YEARS 
 
TOTAL 
 
n =  122 
126 - 200 16 23 13 4 56 (46%) 
201 – 300 9 9 2 1 21 (21%) 
> 300 4 8 3 - 15 (12%) 
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DISCUSSION 
The total number of patients analysed were 122, out of which 53% were Male and 
47% were Female patients. The mean age of patients found in the study was 54 
years. These findings correlate with studies done by Raheja et al (2001) 25 which 
showed the mean age of 53.3 years and another stud by National Rural Diabetic 
Survey of 1989-91 which showed mean age of subjects with diabetes with 52.3 
years 26. In the present study, the mean age of newly diagnosed diabetes is found 
to be 50 years. 
 
The prevalence of diabetes increases with age. The prevalence of diabetes in 
elderly patients in the study is 24% with maximum cases in elderly being 61 – 70 
years age group. This finding correlate with study done by Ahuja MMS (1996) 27 
Epidemological Studies of DM in India showed prevalence of diabetes in elderly 
patients (Age > 60 yrs) in urban population as 23.4% and maximum prevalence 
was in age group of 61 – 69 years. 
 
Out of 122 patients 31% cases had positive family history of Diabetes. Many 
Indian studies show strong association of positive family history in DM type 2. 
These findings correlate with study of Shah et al (1999)28 which showed positive 
family history of 24.9% and Ramachandran et al (1999)29 which showed strong 
correlation of positive family history with DM type 2. 
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RISK FACTORS 
HYPERTENSION 
The prevalence of hypertension in diabetes in the present study is 72%. Out of the 
total 88 patients with hypertension, 61% patients had hypertension at the time of 
diagnosis. The studies done by Banerjee et al (2001)30 found 50% with 
hypertension. CDC’s National Diabetes Survillance System 2005, USA31 shows 
62.5% of patients have hypertension in diabetes. Among the stages of 
hypertension according to JNC VII report, maximum patients 53% were in Stage 
1. Various Indian studies show prevalence of hypertension in DM to be around 50 
– 80%. 
 
OBESITY 
This study shows that 57% patients were over weight and obese according to BMI. 
But when waist circumference was taken 68% patients had abdominal obesity. 
This correlates with a study done by Channaraya et al (2002)32 which showed 
trunkal obesity based on waist circumference was 69%. Many of Indian studies 
showed strong correlation between obesity and DM Type 2. 
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SMOKING 
20% of patients in the present study were smokers and all of them were males. A 
study by SV Madhu et al (2002)33 showed smokers to be 15% and an International 
study by CDC – National Diabetes Surveillance System, 2005, USA31 shows 
smokers at 17.7% among diabetic patients. 
 
HYPERCHOLESTEROLEMIA 
Out of 122 patients 74% patients had hypercholesterolemia. 61% of patients had 
hypercholesterolemia at the time of diagnosis. This study correlates with a study 
done by S.Shafiq et al (2001)34 which showed hypercholesterolemia of 78% and 
CDC – National Diabetes Surveillance System, 2005, USA31 which showed the 
hypercholesterolemia at 60%. 
 
The most common risk factor in Diabetes is hypercholesterolemia which is 74%. 
Next common risk factor is hypertension. All these risk factors play a significant 
rolein the pathogenesis of Macrovascular complications. The risk factor – 
Hypertension  - 61%, Obesity – 51% and hypercholesterolemia – 61% were 
present at the time of diagnosis.  
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MICROVASCULAR COMPLICATIONS 
 
Diabetic Retinopathy 34% is the most common microvascular complication. Out 
of the patients with retinopathy, 88% had non-proliferative retinopathy. The 
prevalence of retinopathy increases according to the duration of diabetes. This 
study correlates with the studies done by G. Premalatha, V Mohan et al (2002)35 
in Urban South Indian Population which showed that Retinopathy was 34.1% and 
M.Ranka et al (2004)36 found it to be 28.9% in a North Indian study. 
 
CKD in Diabetes was seen in 32% of patients in the study. Out of the patients with 
CKD, maximum patients i.e., 43% were in Stage 1. 18% of them had Proteinuria. 
Microalbuminuria was not done in this study. The finding however correlates with 
the study done by Ramachandra et al (1999)29 which showed prevalence of 
Proteinuria at 19.7%.  
 
Diabetic Neuropathy was prevalent in 20% of patients. This finding correlates 
with study done by G.Premalatha, V.Mohan et al  (2002)35 which had 19.1% 
patients with Neuropathy.  
 
A significant finding in the study was Retinopathy 34%, Neuropathy 24% and 
Nephropathy 24% were present at the time of diagnosis. 
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MACROVASCULAR COMPLICATIONS 
 
Coronary Artery Disease – 36% is the most common Macrovascular complication 
in the study. 45% of patients with CAD were asymptomatic in the study. 72% of 
patients with CAD had duration of DM of < 5 years.  
 
Peripheral Vascular Disease was present in 6% of patients in the study. This 
correlates with the study by G.Premalatha, V.Mohan et al (2002)35 which showed 
4%. 
 
Cerebrovascular disease was found in 10% of patients in the study. This correlates 
with the International Study CDC – National Diabetes Surveillance System, 2005, 
USA31  which showed 9% prevalence of stroke in DM type 2. 
 
 
 
 
 
 
 
 
 
 49
CONCLUSION 
 
1. In this study 53% of patients were males and 47% were females, all of them 
being above 35 years of age. The mean age of the Patients was 54 years. 
 
2. The highest number of patients with diabetes was in the age group of 41 – 60 
years.  
 
3. 85% of Patients had duration of diabetes < 5 years. 
 
4. Hypertension was found in 62% of patients.  
 
5. Obesity was found in 57% of patients. 
 
6. Smoking was found in 20% of patients. 
 
7. Hypercholestrolemia was found in 74% of patients.  
 
8. The highest risk factor was Hypercholestrolemia followed by Hypertension. 
 
9. Retinopathy was found in 34% of the Patients. 
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10. Neuropathy was found in 20% of the Patients. 
 
11. Nephropathy was found in 32% of the DM patients.  
 
12. The most common Microvascular Complication was Retinopathy.  
 
13. Newly diagnosed DM patients presented with Retinopathy in 34%, Neuropathy 
in 24% and Nephropathy in 24%.  
 
14. Coronary artery disease was found in 36% of Patients.  
 
15. Peripheral Vascular Disease was found in 6% of patients. 
 
16. Cerebrovascular Disease was found in 10% of patients.  
 
17. The most common Macrovascular Complication is coronary artery disease.  
 
18. Significant number of patients with coronary artery disease presented by 
patients with < 5 Years duration of DM.  
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PROFORMA 
 
DIABETES MELLITUS TYPE 2 – EVALUATION OF MICROVASCULAR AND 
MACROVASCULAR COMPLICATIONS  
 
Name:     Age:     Sex: 
 
 
OPNo.    Diabetology OP No: 
 
HISTORY TAKING 
 
Type of Diabetes Melitus: 
 
Duration of Diabetes Melitus: 
 
History & Duration of Hypertension: 
 
H/o Anginal Chest Pain: 
 
H/o Previous treatment for M1: 
 
H/o Smoking: 
 
H/o taking treatment for complications- 
 
H/o Stroke 
 
H/o TIA 
 
Family H/o Diabetes Mellitus 
 
GENERAL EXAMINATION 
 
Height: 
 
Weight: 
 
Waist Circumference: 
 
  
 
 
VITALS 
 
Pulse: Rate, Rhythm, Felt in all peripheral palpable vessels. 
 
B.P.: 
 
EXAMINATION OF SYSTEM: 
 
CARDIOVASCULAR SYSTEM 
   
   APICAL IMPULSE: 
 
   HEART SOUNDS: 
 
   ADDED SOUNDS: 
 
RESPIRATORY SYSTEM: 
 
  BREATH SOUNDS: 
 
  ADDED SOUNDS: 
 
ABDOMEN: 
   
  ORGANOMECIALY: 
 
  FREE FLUID 
 
CENTRAL NERVOUS SYSTEM 
 
  Higher Fuction: 
 
  Cranial Nerves: 
 
  Motor System: 
 
  Sensory System: 
 
  Spine & Cranium: 
 
  
OPTHALMOLOGICAL EXAMINATION OF FUNDUS 
 
 
INVESTIGATION 
 
Blood Sugar -  Fasting: 
   
-  PP (2Hrs) : 
 
Blood Urea: 
Serum Creatinine: 
Total Cholesterol: 
Urine Albumin: 
24Hrs Urine Protein: 
 
ECG 
 
 
ECHO 
 
 
Doppler Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AGE & SEX DISTRIBUTION
3
19
27
14
22
19 22
11
35
38
49
25
5
0
10
20
30
40
50
60
35-40 41-50 51-60 61-70 >70
AGE GROUP
PE
R
C
EN
TA
G
E
Male Female Total
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DURATION OF DM
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RISK FACTORS AND DM
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MICROVASCULAR COMPLICATIONS & 
DURATION OF DM
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MACROVASCULAR COMPLICATION & DM
44
7
12
CAD   PVD CVA
   
MASTER CHART 
 
S.N
o. 
Age S
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x 
Dura
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of 
DM 
HT
N 
H/o 
Smo
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CA
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DM 
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d 
Sug/
PP 
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tinin
e 
Tot. 
Chol 
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ea 
Alb 
Urin
e 
Prot
ein 
ECG Ech
o 
1 61 M Nu - - - - - - - 170 58 90 110/ 
70 
- 262 300 26 0.6 251 Nil - N - 
2 45 F Nu - - - - - - - 156 85 96 150/ 
100 
NPR 195 281 19 0.3 351 Nil - N - 
3 60 F 6Yr 3Yr - - - - - - 145 55 97 120/ 
70 
- 326 385 33 0.5 329 Nil  N - 
4 68 M 5Yr - √ √ - - √ - 154 60 100 140/ 
90 
- 340 339 23 0.6 189 Nil - N - 
5 65 F 5Yr - - - - - - - 150 65 100 130/ 
80 
- 106 310 32 0.8 186 Nil  N - 
6 55 F Nu Nu - - - - - - 149 60 87 150/ 
90 
- 99 237 62 1.5 173 Nil  N - 
7 72 F 6Yr 2Yr - - - - - - 152 64 88 140/ 
100 
- 121 224 28 0.7 215 Nil  N - 
8 48 M Nu - √ - - - - - 175 80 106 110/ 
80 
- 256 277 31 0.7 158 Nil  N - 
9 44 M Nu Nu √ - - - - √ 169 63 86 140/ 
100 
NPR 271 394 32 0.5 262 Nil  N - 
10 70 F Nu 1Yr - - - - - - 149 73 103 170/ 
100 
- 128 200 34 0.8 239 Nil  IHD N 
11 60 F 4Yr 4Yr - - - - - - 153 48 82 140/ 
80 
- 250 397 29 0.5 123 1 +  N - 
12 38 M 9Yr 9Yr √ - - -  √ 163 44 68 110/ 
70 
NPR 250 309 33 0.6 222 Nil  N - 
13 45 M Nu Nu √ - - - - - 160 65 98 130/ 
90 
- 89 242 47 0.8 317 Nil  N - 
14 55 M 2Yr - √ √ - - - - 165 65 96 130/ 
80 
- 220 280 30 1.0 331 Nil  B N 
15 45 F 2Yr 2Yr - - - - - - 157 48 90 170/ 
90 
- 284 300 20 0.6 284 2 + Y N - 
16 62 F Nu - - - - - - - 145 55 104 120/ 
80 
- 164 294 21 0.4 267 Nil  IHD H 
  
17 57 M Nu Nu  √ - - - - 162 58 82 150/ 
80 
- 96 215 18 0.6 95 1+  IHD DD 
18 60 F Nu -  - - - - √ 145 65 97 130/ 
80 
- 260 340 27 1.1 305 1+ Y IHD N 
19 70 M Nu N  - - - - - 166 55 84 160/ 
90 
 174 223 44 1.1 221 Nil  IHD - 
20 40 F Nu Nu/1
0m 
- - - - - √ 157 56 96 150/ 
90 
- 250 302 29 0.9 368 Nil  IHD - 
21 50 F Nu Nu -  - - √F  153 60 98 130/ 
80 
- 147 264 18 0.9 197 1+ Y N - 
22 45 F 2Yr N - - - - -  154 65 106 140/ 
100 
- 154 301 20 0.8 325 Nil  N - 
23 40 M Nu 2Yr - - - - √  164 65 98 150/ 
100 
- 112 237 26 0.9 177 Nil  IHD DD 
24 53 F 15Y
r 
15Y
r 
- √ - - -  143 56 93 160/ 
100 
- 221 319 14 0.6 327 Nil  OMI H 
25 42 F 8 Yr - - - - - -  153 53 85 130/ 
90 
NPR 208 264 44 1.1 306 1+ Y N - 
26 50 F 2Yr N - - - - -  154 46 85 160/ 
90 
- 248 234 45 0.9 230 1+ Y B N 
27 47 F 15Y
r 
6Yr - - - - √  155 55 92 140/ 
90 
- 104 216 18 0.6 458 1+ Y N - 
28 70 F Nu N - - - - -  150 56 104 160/ 
100 
M 123 249 21 0.9 203 1+ Y N - 
29 48 M 8Yr - - - - - √ √ 157 56 97 110/ 
70 
 250 300 21 1.1 313 2+ Y N - 
30 62 M Nu - - - - - - - 156 55 90 120 
80 
- 156 250 16 0.7 271 1+ Y N - 
31 43 M 1Yr 3Yr  -    √ 173 64 91 136/ 
90 
- 248 267 21 0.8 264 Nil  IHD N 
32 37 M Nu - - - - - - - 167 75 101 110/ 
70 
- 91 269 20 1.1 407 Nil  N - 
33 70 M Nu - - √ - - -  170 70 106 140/ 
90 
- 176 247 27 0.9 256 Nil  B - 
34 45 F Nu - - - - √ - -- 157 65 95 110 
70 
- 200 327 28 0.6 193 Nil  N - 
35 52 M Nu - √ √ - - - √ 165 68 104 120/ 
80 
- 126 259 32 0.9 197 Nil  OMI H 
36 35 F Nu - - - - - - - 155 56 90 110/ 
70 
- 257 304 18 0.6 134 Nil  IHD N 
  
37 45 F 5Yr 5Yr  √ - - - √ 162 62 95 130/ 
90 
- 264 274 26 0.6 242 Nil  IHD DD 
38 35 F Nu - - -    √ 160 54 79 120/ 
80 
- 193 282 17 0.6 169 Nil  IHD N 
39 54 M 1½Y
r 
 √ - - - - -- 175 66 97 120/ 
70 
NPR 96 301 54 1.0 215 Nil  N - 
40 59 M 5Yr N - - - - - - 165 80 112 170/ 
100 
- 116 249 26 0.7 232 Nil  N - 
41 47 M 2Yr N √ - - - - - 165 60 90 150/ 
100 
NPR 196 236 25 0.9 303 Nil  IHD N 
42 60 M Nu - - - - - √ √ 163 48 80 110/ 
60 
- 124 309 20 0.8 134 Nil  N - 
43 57 M 3Yr N √ - - - - √ 165 57 88 150/ 
90 
- 248 279 25 0.9 173 Nil  N - 
44 43 M 7Yr √      √ 180 67 89 130/ 
90 
NPR 160 180 18 0.6 287 Nil  N - 
45 40 M 3Yr 4Yr  - - - - √ 155 55 87 140/ 
90 
NPR 119 301 22 0.6 179 Nil  N - 
46 78 M 5Yr 1Yr √ - - - - - 167 67 100 130/ 
90 
- 114 309 23 0.6 250 Nil  N - 
47 43 M 4Yr 1Yr - - - - - - 180 56 78 130/ 
80 
- 299 339 19 0.6 195 Nil  N - 
48 60 M Nu Nu - - - - - - 162 66 101 210/ 
100 
- 99 209 36 1.2 227 1+ Y N - 
49 45 F Nu 1Yr - - - - - - 157 77 106 130/ 
80 
- 129 210 21 0.7 210 Nil  N - 
50 65 M Nu  √ - - - √ - 165 54 86 140/ 
90 
NPR 287 311 45 1.0 200 Nil  N - 
51 37 M 7Yr - √ - - - - √ 164 57 80 120/ 
70 
NPR 267 310 27 0.7 339 Nil  N - 
52 55 M Nu - √ - - - √ - 165 54 86 140/ 
90 
NPR 81 247 25 0.6 308 Nil  N - 
53 35 M 1Yr -      √ 171 83 108 120/ 
90 
- 163 324 28 0.6 301 Nil  N - 
54 58 M 2Yr 2Yr - - - - -  173 75 102 150/ 
90 
- 123 142 34 0.9 149 Nil  N - 
55 54 F 3Yr 3Yr - - -  √ √ 157 60 94 130/ 
90 
- 309 392 15 0.6 360 Nil  N - 
56 54 M 3Yr - - - - - - - 160 49 82 130/ 
90 
 274 301 23 0.7 164 Nil  N - 
  
57 40 F Nu - - - - - √ - 159 75 114 110/ 
70 
 215 264 28 0.9 233 Nil  N - 
58 69 M 15Y
r 
N √     √ 165 57 89 170/ 
90 
- 143 269 19 0.6 179 Nil  N - 
59 50 F 4Yr  √ - - - √ - 155 50 83 110/ 
70 
- 235 314 27 0.7 271 Nil  IHD N 
60 44 F Nu - - - - - √ - 155 69 101 120/ 
80 
- 163 208 25 0.7 234 Nil  N - 
61 40 M 5Yr - - - - - √ - 169 92 115 130/ 
70 
- 183 324 21 0.4 264 Nil  N - 
62 75 M 4Yr - - - - - -  163 55 92 140/ 
90 
NPR 276 394 26 0.5 163 1+ Y N - 
63 45 M 5Yr 5Yr √ √ - - - √ 160 69 97 140/ 
90 
NPR 243 300 27 0.6 227 2+ Y N - 
64 45 M 10Y
r 
6 
Mo 
- √     167 70 96 150/ 
90 
M 238 301 35 1.0 156 2+ Y IHD H 
65 69 M Nu - √ √ - - - - 170 65 94 120/ 
70 
- 130 227 18 0.6 236 Nil  OMI H 
66 65 F 10Y
r 
- - - - - - √ 142 43 81 120/ 
70 
- 124 324 26 0.6 303 Nil  IHD DD 
67 43 F Nu - √  - - - √ 147 69 99 150/ 
100 
NPR 127 241 51 0.9 199 1+ Y IHD N 
68 70 M Nu - - - - - - - 173 55 87 120/ 
70 
M 168 200 13 0.6 309 Nil  N - 
69 60 M Nu - √ - - - - - 170 70 96 140/ 
86 
NPR 177 223 25 1.0 175 Nil  B N 
70 45 F Nu - - - - - √ - 145 44 73 100/ 
70 
NPR 92 262 23 0.7 130 Nil  N - 
71 40 F 1½Y
r 
- - - - - - - 150 57 84 130/ 
70 
- 135 246 75 0.8 168 Nil  N - 
72 57 F 6 
Mo 
N - - - - √ - 150 65 100 150/ 
100 
- 87 197 24 0.7 211 Nil  N - 
73 40 M Nu - - - - - - - 160 56 85 100/ 
70 
- 134 262 28 1.0 218 Nil  N - 
74 47 M 10 
Yr 
- - - - - - √ 155 55 86 120/ 
70 
NPR 160 244 24 0.8 220 Trac
e 
 N - 
75 38 F 1 Yr - - - - - - - 150 50 82 120/ 
70 
NPR 180 277 13 0.6 260 Nil  N - 
76 63 M 3Yr Nu √ √ - - - √ 155 54 87 130/ 
70 
- 240 339 26 0.6 190 Nil  IHD N 
  
77 60 F 1Yr - - - - - - - 152 80 97 120/ 
70 
- 196 296 24 0.8 197 1+ Y N - 
78 76 M 5 Yr 3 Yr - - - - - - 170 85 115 140/ 
80 
- 198 264 25 0.6 220 Nil  N - 
79 39 M Nu - √ √ - - - √ 165 60 86 130/ 
70 
- 200 267 26 0.9 218 Nil  IHD N 
80 59 M 10Y
r 
5 
Yr 
 -  - - - 172 80 100 140/ 
100 
- 156 210 24 0.7 211 1+ Y N - 
81 65 F 12Y
r 
4 
Yr 
- √ - - √ √ 147 67 96 150/ 
100 
- 172 201 28 0.6 210 Nil  IHD DD 
82 51 M 4 
Yr 
2 
Yr 
- - - -  - 158 76 100 140/ 
90 
- 156 210 27 0.8 220 Nil  N - 
83 54 M 5Yr - √ - - - - - 162 70 96 140/ 
80 
- 140 201 24 0.6 211 Nil  N - 
84 69 M 20Y
r 
- √ - - - - √ 168 72 94 130/ 
70 
NPR 156 200 23 0.8 240 Nil  N - 
85 44 M 5Yr √ - - - - √ √ 157 68 90 130/ 
70 
- 130 201 28 1.0 303 Nil  N - 
86 45 F 3Yr - - - - - - √ 149 65 89 130/ 
70 
- 152 324 23 0.6 236 1+ Y N - 
87 50 F Nu Nu - - - - - - 148 64 87 150/ 
100 
NPR 177 241 18 0.4 197 Nil  N - 
88 67 M 3Yr 2Yr - - - - √ √ 162 70 100 150/ 
100 
- 160 200 29 0.6 200 Nil  N - 
89 61 M 10Y
r 
5 Yr √ - - - - - 160 52 86 154/ 
100 
- 172 217 27 0.8 210 Nil  N - 
90 50 M Nu Nu - - - - √ √ 157 68 105 160/ 
100 
- 140 203 24 0.6 250 Nil  N - 
91 48 M 5Yr 5Yr √ √ - - - - 160 72 102 150/ 
100 
NPR 156 198 22 0.7 196 Nil  IHD N 
92 58 F 3 Yr 5Yr - - - - - √ 152 66 96 130/ 
90 
- 96 140 28 1.0 220 Nil  N - 
93 50 F 5Yr 5Yr - - - - √ - 150 60 100 100/ 
70 
NPR 110 186 45 1.0 236 Nil  N - 
94 45 F 3Yr - - - - - - √ 155 45 85 140/ 
90 
NPR 112 176 28 0.6 303 3+ Y N - 
95 60 F 4yr 4yr - √ - - - - 153 62 95 170/ 
100 
NPR 156 200 27 0.8 256 3+ Y OMI H 
96 54 F 1Yr 1Yr - √ - - - √ 156 64 96 150/ 
100 
- 125 201 24 0.9 224 Nil  IHD N 
  
97 57 F 11Y
r 
5Yr - √ - - - - 152 60 106 150/ 
90 
NPR 156 174 30 1.2 210 1+ Y IHD - 
98 60 M 15Y
r 
5Yr  √ - - - √ 160 70 92 160/ 
100 
- 172 196 40 1.5 200 1+ Y OMI H 
99 56 M 12Y
r 
2Yr √ √ - - - - 158 68 104 140/ 
90 
NPR 146 206 28 1.6 240 Nil  IHD DD 
100 55 F 9Yr 1Yr - √ -  √ - 148 62 90 140/ 
90 
- 172 252 32 1.6 460 Nil  OMI H 
101 56 F 14Y
r 
14Y
r 
- - - - - - 149 64 96 140 
90 
NPR 154 264 42 1.5 196 Nil  N - 
102 58 F 10Y
r 
2Yr      √ 152 60 92 130/ 
100 
- 162 276 20 1.0 198 Nil  N - 
103 48 F 10Y
r 
5Yr - √ - - √ - 154 62 94 150/ 
100 
NPR 200 282 29 1.5 220 Nil  OMI H 
104 49 M 8Yr 2Yr - - - - - - 164 65 102 146/ 
90 
NPR 148 256 30 1.6 260 Nil  N - 
105 52 M 12Y
r 
6Yr √ - - - - - 166 80 104 130/ 
90 
- 260 290 32 1.4 220 1+ Y N - 
106 62 M 15Y
r 
15Y
e 
√ √ - - √ - 158 76 106 180/ 
100 
NPR 156 200 40 1.6 224 Nil  IHD N 
107 60 M 10Y
e 
4Yr - - - - - - 156 72 108 140/ 
90 
- 162 202 42 1.6 226 Nil  N - 
108 56 M Nu Nu - √ - - - √ 162 70 98 180/ 
100 
NPR 156 204 28 0.9 198 Nil  N - 
109 52 M 5Yr - - - - - - - 164 86 106 140/ 
90 
NPR 178 260 40 1.7 240 Nil  N - 
110 65 F 13Y
r 
3Yr - - - - √ - 152 56 98 150/ 
90 
NPR 142 196 28 1.2 226 Nil  N - 
111 56 F 6Yr - - - - -  - 156 70 96 140/ 
90 
- 156 242 26 0.9 210 Nil  N - 
112 54 M 9Yr 4Yr  √ - - - √ 160 72 100 130/ 
90 
-- 178 256 30 1.2 202 1+ Y OMI - 
113 56 F 5Yr 5Yr -- - - -  - 149 56 96 150/ 
100 
NPR 156 200 20 0.9 200 Nil  IHD - 
114 58 F 6Yr - - - - - - - 152 60 98 140/ 
92 
- 172 206 20 0.8 260 Nil  N - 
115 57 F Nu Nu - -- - - - √ 154 62 96 160/ 
100 
 182 208 28 0.9 192 Nil  OMI H 
116 58 M 8Yr 5Yr  √ - - - - 158 58 94 156/ 
100 
NPR 167 210 40 1.8 252 2+  OMI H 
  
117 52 F 4Yr - - - - - - - 146 58 96 130/ 
90 
- 156 196 26 1.0 220 Nil  N - 
118 50 F Nu Nu - - - - - - 148 60 100 150/ 
100 
PR 162 211 28 1.1 240 Nil  N - 
119 62 F 10Y
r 
2Yr - - - - √ √ 152 60 92 180/ 
100 
PR 172 256 28 1.2 226 Nil  N - 
120 64 F 12Y
r 
10Y
r 
- - - - - - 151 62 94 150/ 
90 
- 174 300 26 1.3 230 Nil  N - 
121 60 F 8Yr 2Yr - - - - - - 150 56 86 156/ 
90 
- 176 272 28 1.6 236 Nil  N - 
122 54 F 5Yr - - - - - - - 149 65 96 140/ 
90 
- 178 296 26 1.5 240 Nil  N - 
 
Abbreviations Used:  Nu – New; NPR -  Non Proliferative Retinopathy; PR -  Proliferative Retinopathy; M – Maculopathy; N – Normal; B – Block; IHD -  Ischaemic Heart Disease;  
OMI – Old Myocardinal Infraction; DD – Diastolic Dysfunction; H – Hypokinetic Wall Motion Abnormalities. 
